George Myers, MD
Cardiovascular Disease · Rome, GANPI 1982766630
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,605 of the $5,192 with a category attached, or 88.7%. 30 manufacturers reported payments, led by Johnson & Johnson at 29.3% of the total. Reporting peaked in 2019 at $1,309 and has fallen 76.9% since, to $303 in 2025.
Across 359 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Medtronic$1K
- Boston Scientific$550
- Novartis$297
- Abbott$216
- Cvrx, Inc.$171
- plus $1K from 24 others
Across 9 payments — averaging $1172.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$11K
What the payments were for
- Travel & lodging$57011%
- Food & beverage$4,60589%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 227 | $1,519 |
| Medtronic(2 entities) | 22 | $1,166 |
| Boston Scientific | 24 | $550 |
| Novartis | 16 | $297 |
| Abbott | 6 | $216 |
| Cvrx, Inc. | 2 | $171 |
| E.r. Squibb & Sons, L.L.C. | 11 | $160 |
| AstraZeneca | 2 | $138 |
| Actelion Pharmaceuticals US, Inc. | 2 | $138 |
| Abiomed | 4 | $123 |
| Pfizer | 8 | $115 |
| Shockwave Medical, Inc | 3 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $74 |
| Lexicon Pharmaceuticals, Inc. | 4 | $71 |
| Boehringer Ingelheim | 3 | $62 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Amgen | 3 | $49 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Cardiovascular Systems Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Biotronik Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Bayer | 1 | $13 |
| Chiesi USA, Inc. | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,192 in reported general payments places this provider in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 555 | $492,087 |
| XareltoRivaroxaban | 310 | $301,433 |
| EntrestoSacubitril/Valsartan | 77 | $107,303 |
| FarxigaDapagliflozin Propanediol | 44 | $36,191 |
| Repatha SureclickEvolocumab | 30 | $20,649 |
| BrilintaTicagrelor | 24 | $14,251 |
| Ranolazine ErRanolazine | 84 | $8,294 |
| Amiodarone Hcl | 356 | $7,024 |
| ClopidogrelClopidogrel Bisulfate | 563 | $6,258 |
| Praluent PenAlirocumab | 12 | $5,917 |
| Nitroglycerin | 205 | $3,687 |
| Atorvastatin Calcium | 381 | $3,510 |
| Furosemide | 640 | $2,854 |
| Carvedilol | 374 | $2,733 |
| Metoprolol Tartrate | 417 | $2,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $492,087555 claims |
| Johnson & JohnsonXarelto | $1,519 | $301,433310 claims |
| NovartisEntresto | $297 | $107,30377 claims |
| AstraZenecaFarxiga, Brilinta | $138 | $50,44268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Rome
- Charles JacksonRome$17K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.